SERPINE1 and diabetic kidney disease: Recently developed anti-PAI-1 monoclonal antibodies (MEDI-579 and AS3288802) to the RCL efficiently block PAI-1 activity and show nephroprotective effects in mouse models of diabetic nephropathy and lupus nephritis46, 47.